118 related articles for article (PubMed ID: 37768670)
21. Assessment of Capecitabine and Bevacizumab With or Without Atezolizumab for the Treatment of Refractory Metastatic Colorectal Cancer: A Randomized Clinical Trial.
Mettu NB; Ou FS; Zemla TJ; Halfdanarson TR; Lenz HJ; Breakstone RA; Boland PM; Crysler OV; Wu C; Nixon AB; Bolch E; Niedzwiecki D; Elsing A; Hurwitz HI; Fakih MG; Bekaii-Saab T
JAMA Netw Open; 2022 Feb; 5(2):e2149040. PubMed ID: 35179586
[TBL] [Abstract][Full Text] [Related]
22. Docetaxel, cisplatin and 5-fluorouracil induction chemotherapy followed by chemoradiotherapy or chemoradiotherapy alone in stage III-IV unresectable head and neck cancer: Results of a randomized phase II study.
Takácsi-Nagy Z; Hitre E; Remenár É; Oberna F; Polgár C; Major T; Gödény M; Fodor J; Kásler M
Strahlenther Onkol; 2015 Aug; 191(8):635-41. PubMed ID: 25782685
[TBL] [Abstract][Full Text] [Related]
23. Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With ≥ 2 HER2-Directed Regimens: Phase III NALA Trial.
Saura C; Oliveira M; Feng YH; Dai MS; Chen SW; Hurvitz SA; Kim SB; Moy B; Delaloge S; Gradishar W; Masuda N; Palacova M; Trudeau ME; Mattson J; Yap YS; Hou MF; De Laurentiis M; Yeh YM; Chang HT; Yau T; Wildiers H; Haley B; Fagnani D; Lu YS; Crown J; Lin J; Takahashi M; Takano T; Yamaguchi M; Fujii T; Yao B; Bebchuk J; Keyvanjah K; Bryce R; Brufsky A;
J Clin Oncol; 2020 Sep; 38(27):3138-3149. PubMed ID: 32678716
[TBL] [Abstract][Full Text] [Related]
24. Induction chemotherapy with lobaplatin and fluorouracil versus cisplatin and fluorouracil followed by chemoradiotherapy in patients with stage III-IVB nasopharyngeal carcinoma: an open-label, non-inferiority, randomised, controlled, phase 3 trial.
Lv X; Cao X; Xia WX; Liu KY; Qiang MY; Guo L; Qian CN; Cao KJ; Mo HY; Li XM; Li ZH; Han F; He YX; Liu YM; Wu SX; Bai YR; Ke LR; Qiu WZ; Liang H; Liu GY; Miao JJ; Li WZ; Lv SH; Chen X; Zhao C; Xiang YQ; Guo X
Lancet Oncol; 2021 May; 22(5):716-726. PubMed ID: 33857411
[TBL] [Abstract][Full Text] [Related]
25. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer.
Johnston S; Pippen J; Pivot X; Lichinitser M; Sadeghi S; Dieras V; Gomez HL; Romieu G; Manikhas A; Kennedy MJ; Press MF; Maltzman J; Florance A; O'Rourke L; Oliva C; Stein S; Pegram M
J Clin Oncol; 2009 Nov; 27(33):5538-46. PubMed ID: 19786658
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and Safety of Locoregional Radiotherapy With Chemotherapy vs Chemotherapy Alone in De Novo Metastatic Nasopharyngeal Carcinoma: A Multicenter Phase 3 Randomized Clinical Trial.
You R; Liu YP; Huang PY; Zou X; Sun R; He YX; Wu YS; Shen GP; Zhang HD; Duan CY; Tan SH; Cao JY; Li JB; Xie YL; Zhang YN; Wang ZQ; Yang Q; Lin M; Jiang R; Zhang MX; Hua YJ; Tang LQ; Zhuang AH; Chen QY; Guo L; Mo HY; Chen Y; Mai HQ; Ling L; Liu Q; Chua MLK; Chen MY
JAMA Oncol; 2020 Sep; 6(9):1345-1352. PubMed ID: 32701129
[TBL] [Abstract][Full Text] [Related]
27. Debio 1143 and high-dose cisplatin chemoradiotherapy in high-risk locoregionally advanced squamous cell carcinoma of the head and neck: a double-blind, multicentre, randomised, phase 2 study.
Sun XS; Tao Y; Le Tourneau C; Pointreau Y; Sire C; Kaminsky MC; Coutte A; Alfonsi M; Boisselier P; Martin L; Miroir J; Ramee JF; Delord JP; Clatot F; Rolland F; Villa J; Magne N; Elicin O; Gherga E; Nguyen F; Lafond C; Bera G; Calugaru V; Geoffrois L; Chauffert B; Zubel A; Zanna C; Brienza S; Crompton P; Rouits E; Gollmer K; Szyldergemajn S; Bourhis J
Lancet Oncol; 2020 Sep; 21(9):1173-1187. PubMed ID: 32758455
[TBL] [Abstract][Full Text] [Related]
28. Association of Surgical Margin Distance With Survival in Patients With Resected Head and Neck Squamous Cell Carcinoma: A Secondary Analysis of a Randomized Clinical Trial.
Sunkara PR; Graff JT; Cramer JD
JAMA Otolaryngol Head Neck Surg; 2023 Apr; 149(4):317-326. PubMed ID: 36821132
[TBL] [Abstract][Full Text] [Related]
29. Locally advanced head and neck cancer treated with accelerated radiotherapy, the hypoxic modifier nimorazole and weekly cisplatin. Results from the DAHANCA 18 phase II study.
Bentzen J; Toustrup K; Eriksen JG; Primdahl H; Andersen LJ; Overgaard J
Acta Oncol; 2015 Jul; 54(7):1001-7. PubMed ID: 25629651
[TBL] [Abstract][Full Text] [Related]
30. Phase III, Randomized Study of Dual Human Epidermal Growth Factor Receptor 2 (HER2) Blockade With Lapatinib Plus Trastuzumab in Combination With an Aromatase Inhibitor in Postmenopausal Women With HER2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer: Updated Results of ALTERNATIVE.
Johnston SRD; Hegg R; Im SA; Park IH; Burdaeva O; Kurteva G; Press MF; Tjulandin S; Iwata H; Simon SD; Kenny S; Sarp S; Izquierdo MA; Williams LS; Gradishar WJ
J Clin Oncol; 2021 Jan; 39(1):79-89. PubMed ID: 32822287
[TBL] [Abstract][Full Text] [Related]
31. Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study.
Burtness B; Goldwasser MA; Flood W; Mattar B; Forastiere AA;
J Clin Oncol; 2005 Dec; 23(34):8646-54. PubMed ID: 16314626
[TBL] [Abstract][Full Text] [Related]
32. Phase III, Double-Blind, Randomized Trial That Compared Maintenance Lapatinib Versus Placebo After First-Line Chemotherapy in Patients With Human Epidermal Growth Factor Receptor 1/2-Positive Metastatic Bladder Cancer.
Powles T; Huddart RA; Elliott T; Sarker SJ; Ackerman C; Jones R; Hussain S; Crabb S; Jagdev S; Chester J; Hilman S; Beresford M; Macdonald G; Santhanam S; Frew JA; Stockdale A; Hughes S; Berney D; Chowdhury S
J Clin Oncol; 2017 Jan; 35(1):48-55. PubMed ID: 28034079
[TBL] [Abstract][Full Text] [Related]
33. The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy-MONARCH 2: A Randomized Clinical Trial.
Sledge GW; Toi M; Neven P; Sohn J; Inoue K; Pivot X; Burdaeva O; Okera M; Masuda N; Kaufman PA; Koh H; Grischke EM; Conte P; Lu Y; Barriga S; Hurt K; Frenzel M; Johnston S; Llombart-Cussac A
JAMA Oncol; 2020 Jan; 6(1):116-124. PubMed ID: 31563959
[TBL] [Abstract][Full Text] [Related]
34. Neoadjuvant Chemotherapy With Cisplatin and Gemcitabine Followed by Chemoradiation Versus Chemoradiation for Locally Advanced Cervical Cancer: A Randomized Phase II Trial.
da Costa SCS; Bonadio RC; Gabrielli FCG; Aranha AS; Dias Genta MLN; Miranda VC; de Freitas D; Abdo Filho E; Ferreira PAO; Machado KK; Scaranti M; Carvalho HA; Estevez-Diz MDP
J Clin Oncol; 2019 Nov; 37(33):3124-3131. PubMed ID: 31449470
[TBL] [Abstract][Full Text] [Related]
35. Neratinib Plus Paclitaxel vs Trastuzumab Plus Paclitaxel in Previously Untreated Metastatic ERBB2-Positive Breast Cancer: The NEfERT-T Randomized Clinical Trial.
Awada A; Colomer R; Inoue K; Bondarenko I; Badwe RA; Demetriou G; Lee SC; Mehta AO; Kim SB; Bachelot T; Goswami C; Deo S; Bose R; Wong A; Xu F; Yao B; Bryce R; Carey LA
JAMA Oncol; 2016 Dec; 2(12):1557-1564. PubMed ID: 27078022
[TBL] [Abstract][Full Text] [Related]
36. Effect of Standard Radiotherapy With Cisplatin vs Accelerated Radiotherapy With Panitumumab in Locoregionally Advanced Squamous Cell Head and Neck Carcinoma: A Randomized Clinical Trial.
Siu LL; Waldron JN; Chen BE; Winquist E; Wright JR; Nabid A; Hay JH; Ringash J; Liu G; Johnson A; Shenouda G; Chasen M; Pearce A; Butler JB; Breen S; Chen EX; FitzGerald TJ; Childs TJ; Montenegro A; O'Sullivan B; Parulekar WR
JAMA Oncol; 2017 Feb; 3(2):220-226. PubMed ID: 27930762
[TBL] [Abstract][Full Text] [Related]
37. Cisplatin and radiotherapy with or without erlotinib in locally advanced squamous cell carcinoma of the head and neck: a randomized phase II trial.
Martins RG; Parvathaneni U; Bauman JE; Sharma AK; Raez LE; Papagikos MA; Yunus F; Kurland BF; Eaton KD; Liao JJ; Mendez E; Futran N; Wang DX; Chai X; Wallace SG; Austin M; Schmidt R; Hayes DN
J Clin Oncol; 2013 Apr; 31(11):1415-21. PubMed ID: 23460709
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and Safety of Weekly Paclitaxel With or Without Oral Alisertib in Patients With Metastatic Breast Cancer: A Randomized Clinical Trial.
O'Shaughnessy J; McIntyre K; Wilks S; Ma L; Block M; Andorsky D; Danso M; Locke T; Scales A; Wang Y
JAMA Netw Open; 2021 Apr; 4(4):e214103. PubMed ID: 33877311
[TBL] [Abstract][Full Text] [Related]
39. Afatinib vs Placebo as Adjuvant Therapy After Chemoradiotherapy in Squamous Cell Carcinoma of the Head and Neck: A Randomized Clinical Trial.
Burtness B; Haddad R; Dinis J; Trigo J; Yokota T; de Souza Viana L; Romanov I; Vermorken J; Bourhis J; Tahara M; Martins Segalla JG; Psyrri A; Vasilevskaya I; Nangia CS; Chaves-Conde M; Kiyota N; Homma A; Holeckova P; Del Campo JM; Asarawala N; Nicolau UR; Rauch D; Even C; Wang B; Gibson N; Ehrnrooth E; Harrington K; Cohen EEW;
JAMA Oncol; 2019 Aug; 5(8):1170-1180. PubMed ID: 31194247
[TBL] [Abstract][Full Text] [Related]
40. Comparison of 3 Paclitaxel-Based Chemoradiotherapy Regimens for Patients With Locally Advanced Esophageal Squamous Cell Cancer: A Randomized Clinical Trial.
Ai D; Ye J; Wei S; Li Y; Luo H; Cao J; Zhu Z; Zhao W; Lin Q; Yang H; Zheng X; Zhou J; Huang G; Li L; Li J; Zhang Z; Zhou G; Gu D; Du M; Mo M; Jia H; Zhang Z; Zhao K
JAMA Netw Open; 2022 Feb; 5(2):e220120. PubMed ID: 35188552
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
